Literature DB >> 7509075

Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.

X Qian1, C M LeVea, J K Freeman, W C Dougall, M I Greene.   

Abstract

We have shown that members of the erbB family undergo homodimer and heterodimer formation. The rat p185c-neu and the epidermal growth factor receptor (EGFR) can associate into an active heterodimeric tyrosine kinase. Overexpression of these two receptors also results in a transformed phenotype. We now show that mutant Neu proteins resulting from a point mutation at the ATP-binding site (N757) or cytoplasmic domain deletions (N691stop) are still able to undergo EGF-induced heterodimerization with EGFR. Analysis of heterodimer formation between EGFR and truncated Neu proteins revealed that heterodimerization is preferred over homodimerization of EGFR. N757 can be transphosphorylated by associated EGFR upon EGF stimulation. However, the heterodimer composed of EGFR and N691stop is kinase inactive. These results provided evidence that the Neu ectodomain is sufficient to associate with EGFR physically, and the cytoplasmic domain interaction is required for heterodimeric kinase activation, indicating that Neu/c-erbB2 is not just a simple substrate for EGFR but a transactivator as well.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509075      PMCID: PMC43187          DOI: 10.1073/pnas.91.4.1500

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation.

Authors:  J D Kelly; B A Haldeman; F J Grant; M J Murray; R A Seifert; D F Bowen-Pope; J A Cooper; A Kazlauskas
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

Review 2.  A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization.

Authors:  M J Sternberg; W J Gullick
Journal:  Protein Eng       Date:  1990-03

3.  Characterization of a neu/c-erbB-2 protein-specific activating factor.

Authors:  K Dobashi; J G Davis; Y Mikami; J K Freeman; J Hamuro; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

4.  Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells.

Authors:  A M Honegger; A Schmidt; A Ullrich; J Schlessinger
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

5.  Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation.

Authors:  J D Bjorge; T O Chan; M Antczak; H J Kung; D J Fujita
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

6.  A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization.

Authors:  O Kashles; Y Yarden; R Fischer; A Ullrich; J Schlessinger
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

7.  Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation.

Authors:  R Goldman; R B Levy; E Peles; Y Yarden
Journal:  Biochemistry       Date:  1990-12-18       Impact factor: 3.162

8.  The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.

Authors:  P A Connelly; D F Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

9.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

Authors:  M F Press; C Cordon-Cardo; D J Slamon
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

10.  Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.

Authors:  E Peles; R B Levy; E Or; A Ullrich; Y Yarden
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

View more
  36 in total

1.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.

Authors:  R Murali; P J Brennan; T Kieber-Emmons; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 2.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.

Authors:  T Kumagai; J G Davis; T Horie; D M O'Rourke; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

4.  erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.

Authors:  Mara P Steinkamp; Shalini T Low-Nam; Shujie Yang; Keith A Lidke; Diane S Lidke; Bridget S Wilson
Journal:  Mol Cell Biol       Date:  2013-12-30       Impact factor: 4.272

5.  The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development.

Authors:  Richard Chan; William R Hardy; Michael A Laing; Sarah E Hardy; William J Muller
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

6.  Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.

Authors:  Kaoru Kiguchi; Takuya Kitamura; Tricia Moore; Mohammad Rumi; Hsiang-Chun Chang; Devon Treece; Lynnsie Ruffino; Kevin Connolly; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-03

Review 7.  Reversion of the ErbB malignant phenotype and the DNA damage response.

Authors:  E Aaron Runkle; Hongtao Zhang; Zheng Cai; Zhiqiang Zhu; Barry L Karger; Shiaw-Lin Wu; Donald M O'Rourke; Zhaocai Zhou; Qiang Wang; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2012-09-27       Impact factor: 3.362

8.  Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.

Authors:  Chia C Portera; Janice M Walshe; Douglas R Rosing; Neelima Denduluri; Arlene W Berman; Ujala Vatas; Margarita Velarde; Catherine K Chow; Seth M Steinberg; Diana Nguyen; Sherry X Yang; Sandra M Swain
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation.

Authors:  Toru Kumagai; Makoto Katsumata; Akihiro Hasegawa; Keiji Furuuchi; Toshiki Funakoshi; Ichiro Kawase; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-16       Impact factor: 11.205

10.  Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis.

Authors:  Toshimitsu Yamaoka; Fang Yan; Hanwei Cao; Stuart S Hobbs; Rebecca S Dise; Wei Tong; D Brent Polk
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.